The delay accommodates Mr. Mahoney’s post-employment obligations with J&J. He replaces Boston Scientific CEO Ray Elliott, who announced in May that he intended to step down.
Hank Kucheman, currently the executive vice president and group president of the cardiology, rhythm and vascular group at Boston Scientific, will serve as interim CEO until Mr. Mahoney can assume the role full time in fall 2012.
Related Articles on Boston Scientific:
FDA May Revoke Approvals of Transvaginal Mesh Products
Boston Scientific Warns Patients of Non-Sterile, Stolen Devices
